Publication | Closed Access

Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials

HepatologyPhase 2BLiver PhysiologyPharmacologyPlacebo-controlled TrialsNonalcoholic SteatohepatitisHepatotoxicityPharmacotherapyLiver DiseaseHepatology FibrosisFatty Liver DiseaseMedicine